Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report

BACKGROUND: Lenvatinib has been shown to be noninferior to sorafenib regarding prognosis and recurrence rate in patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic chemotherapy. In patients treated with lenvatinib, 40% of cases achieved sufficient tumor red...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokoo, Hideki, Takahashi, Hiroyuki, Hagiwara, Masahiro, Iwata, Hiroyoshi, Imai, Koji, Saito, Yoshinori, Matsuno, Naoto, Furukawa, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772741/
https://www.ncbi.nlm.nih.gov/pubmed/33442460
http://dx.doi.org/10.4254/wjh.v12.i12.1349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772741/
https://www.ncbi.nlm.nih.gov/pubmed/33442460
http://dx.doi.org/10.4254/wjh.v12.i12.1349

Ejemplares similares